Lumida
/ARQT
⌘K
Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

ARQT
$23.89USD+2.16%+0.51 today

MARKET CAP

3.0B

P/E (TTM)

FWD P/E

DAY RANGE

$24 – $24

52W RANGE

$17
$32

AI Summary

Stalk
Sell NowMedium

ARQT is trading in a Stage 3 distribution context, with price below declining EMAs and failing to sustain rallies. Medium-term bias remains bearish, while short-term rejection at the dynamic resistance (9/20/50 EMA zone) signals Sell Now. Extreme oversold readings may provoke relief bounces, but execution favors selling rallies into resistance.

  • Revenue rose 59% YoY to $129.9M in Q2 2026, signaling robust demand
  • Raised full-year 2026 sales guidance to $525–540M vs prior $480–495M
  • Net income $15M vs –$15.9M last year, but margins pressured by reinvestment
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$0$3.7M$59.6M$196.5M$376.1M
YoY %+1517.1%+229.7%+91.3%
P / Sales220.5x4.0x8.6x9.8x
EV / Sales271.0x6.7x9.2x10.4x
Gross Profit, Adj.$0$2.9M$54.6M$177.4M$339.4M
YoY %+1762.9%+224.8%+91.3%
Margin %79.5%91.6%90.3%90.2%
EV / Gross Profit340.7x7.4x10.2x11.5x
EBITDA, Adj.$-136.5M$-300.7M$-241.1M$-128.4M$-12.2M
YoY %-46.1%+19.8%+46.7%+90.5%
Margin %-8157.7%-404.5%-65.3%-3.3%
EV / EBITDA-7.1x-3.3x-1.7x-14.1x-318.6x
EBIT$-136.6M$-301.6M$-241.1M$-128.4M$-12.2M
YoY %-46.0%+20.1%+46.7%+90.5%
Margin %-8183.0%-404.5%-65.3%-3.3%
EV / EBIT-7.1x-3.3x-1.7x-14.1x-318.6x
Net Income$-135.7M$-311.5M$-262.1M$-140.0M$-16.1M
YoY %-50.9%+15.8%+46.6%+88.5%
Net Margin-8449.8%-439.8%-71.3%-4.3%
EPS (GAAP)-$3.80-$5.66-$3.78-$1.16-$0.13
YoY %-35.4%+33.2%+69.3%+88.8%